Biosimilars Viable Only For Blockbuster Biologics?
This article was originally published in PharmAsia News
Executive Summary
A report by economist Brill suggests that high development and compliance costs will limit the range of biosimilars that are developed. The study was funded by pharmacy benefit manager Prime Therapeutics.